NRXP — NRX Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $75.59m
- $82.91m
Annual cashflow statement for NRX Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.09 | -93.1 | -39.8 | -30.1 | -25.1 |
| Depreciation | |||||
| Non-Cash Items | 0.303 | 60.3 | -0.704 | 3.32 | 9.19 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.188 | -4.9 | 0.699 | 5.16 | 5.29 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.599 | -37.7 | -39.8 | -21.7 | -10.6 |
| Capital Expenditures | — | -0.007 | -0.01 | -0.003 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 26.2 | — | — | — | — |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 26.2 | -0.007 | -0.01 | -0.003 | 0 |
| Financing Cash Flow Items | — | 11.1 | 0 | 0 | 3.39 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -25.6 | 63.5 | 32.2 | 6.2 | 7.49 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 25.7 | -7.55 | -15.5 | -3.15 |